In this article, Julie Maréchal-Jamil, Director, Biosimilar Policy & Science, Medicines for Europe, explores the strategies needed at European and national levels to secure the benefits of biosimilar medicines in an evolving landscape to deliver a pipeline for these drugs by 2030.
Since 2006, the advent of biosimilar competition in Europe has played an essential and growing role in catalysing patient access to key biological medicines (around seven billion safe and effective treatment days) while achieving significant relief for healthcare budgets amounting to €56 billion in cumulative biological treatment cost reductions across Europe (approx. €6 billion in 2024 alone). Over 100 biosimilar medicines are approved for nearly 30 reference medicines, testimony to the rigour of the scientific standards leading to the European authorisation process.
This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.
Key learning points:
Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
Learn about ITM’s implementation journey and considerations when evaluating the technology
Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).
Don’t miss your chance to learn from experts in the industry –Register for FREE
Can’t attend live? No worries – register to receive the recording post-event.
More importantly, patient outcomes have also been transformative, with more patients getting faster access to biological therapy. Medical societies and payers evolved treatment pathways, notably by removing access limitations (ie, cost-containment measures). These reconsiderations lead the way to liberating untapped potential from biological standards of care.1
With pharmaceutical innovation increasingly focusing on a wider range of biotechnology-derived medicines, a surge in biological medicines losing market exclusivity is expected between now and the end of the decade, creating an opportunity eight times greater than that of the 2012-14 period, (peaking at €30 billion between 2030-2032).2
The upcoming biosimilar wave and evolving challenges
a surge in biological medicines losing market exclusivity is expected between now and the end of the decade, creating an opportunity eight times greater than that of the 2012-14 period”
Even compared to only 10 years ago, the European pharmaceutical landscape has drastically evolved. Biological medicines represent 41 percent of pharmaceutical spending, growing at three times the rate of chemical medicines. This makes biosimilar medicines highly relevant. A significant number of the possible biosimilar candidates are not ‘blockbuster’ medicines. Instead they treat a minority population of patients, either specific indications or by targeting a subset of patients.
There has also been a multiplication of the nature of the biotechnology platforms involved. By the end of the decade, two cell and gene therapies will be subject to follow-on competition for the first time, beginning a whole new chapter in the biosimilar history.
This represents a unique opportunity for Europe to continue leading the way on advancing the biosimilar medicines concept3 both in terms of the health and outcomes opportunities it could bring, as well as in the field of regulatory science, R&D, biotechnological and biomanufacturing progress.
Gaps in the biosimilar pipeline had been recorded already in 2022, pointing to the need to better understand the drivers of biosimilar competition (or its absence) for Europe to sustain future biosimilar benefits.
By the end of [2030], two cell and gene therapies will be subject to follow-on competition for the first time, beginning a whole new chapter in the biosimilar history”
The 2024 IQVIA report4 highlights a dynamic market shaped by competition, but also hindered by structural gaps, including absolute barriers to entry. These findings, presented at the European Commission’s annual biosimilar stakeholder event,5 provide an important reflection point for the future of European and national biosimilar medicines strategies.
To deliver a biosimilar pipeline by 2030, new questions need to be addressed across the biosimilar life cycle: R&D and biomanufacturing investment in new technological platforms, regulatory requirements for biosimilar development (eg, cell and gene, orphan medicines), intellectual property, market competition dynamics, access policies, etc.
The path ahead – should we change tack?
Back in 2015, in the first IQVIA report6 and prompted by Commissioner Tajani’s initiative,7 efforts were made by stakeholders to design a unifying methodology to best define and represent the evolution of access to biosimilar medicines and biosimilar competition dynamics.
… it is important to keep an eye on the biosimilar pipeline activity, assess the competition dynamics and overall market attractiveness, and approach access policies more dynamically”
At the time, there were a limited number of biosimilar medicines in a few therapeutic indications. The methodology rested on two main indicators tracking market performance: the uptake of biosimilars in the industry and whether the cost of treatment is decreasing (price reductions and system savings).
Over time, patient volumes (patient treatment days) and levels of competition, including market share, were also considered. Today, when assessing European Member States’ actual metrics and benchmarks, most are still only focusing on uptake and price evolution.
The unprecedented wave of biologics’ imminent loss of exclusivity both resembles and drastically differs from biosimilar history to date.
It therefore appears not only appropriate but essential, that Europe and individual States move towards a more elaborate and nuanced set of indicators that enables a refined understanding and allows better informed policy-making decisions on the needed evolution of the biosimilar strategies in place.
The AUGMENT Biosimilars project and the AUGMENT Consortium8 captured this idea very well by prioritising the development of a country dashboard for biosimilar medicines policies and their concrete impact.
Besides traditional indicators, it is important to include and monitor new indicators to draw horizon scanning and allow adjustments to budget and savings forecasts. Among these, it is important to keep an eye on the biosimilar pipeline activity, assess the competition dynamics and overall market attractiveness, and approach access policies more dynamically, ie, revise reimbursement policies and treatment paradigm.
Realising the opportunity in the biosimilar landscape
Europe, and the world, are faced with an incredible and unprecedented opportunity to take advantage of biosimilar medicines to broaden access to key biological medicines, allow healthcare systems to invest effectively, while sustaining a thriving biosimilar industrial sector, stimulating technological innovation and progress. The commitment of biosimilar industrial actors to dynamic competition in support of affordability, accessibility, availability, innovation and competitiveness is undisputable.
Coordinated action at both EU and national levels, as well as a renewed focus on policy indicators which effectively reflect the competition dynamics, patient access, and treatment cost reduction are needed. This will provide more regulatory certainty, enhance market predictability and healthy competition to contribute to increasing overall predictability, and act as an incentive to drive the expansion of EU and global investment in biosimilar development and patient benefits.
The key question today for governments and stakeholders to unlock access to the next wave of life-changing biological therapies must therefore revolve around the proactive strategic inclusion of biosimilar medicines policies as part of healthcare and industrial policies, with a clear goal to de-risk and enhance predictability in support of investment in biosimilar medicines development across a broad range of therapies.
About the author
Julie Maréchal-Jamil is Director, Biosimilar Policy & Science at Medicines for Europe. She leverages more than 20 years of experience in the pharmaceutical sector, including over 17 years in policy and advocacy as the head of the Biosimilar Medicines Group, a sector group of Medicines for Europe.
Marechal-Jamil has led European and International advocacy efforts across a wide range of topics: market access and health policies, and regulatory and scientific frameworks. She holds a MSc in Pharmacology.
References
1. Key Figures on Biosimilar medicines (2024). [Internet] Biosimilar Medicines Group, Medicines for Europe. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2024/05/infographic-biosimilars.pdf
2. Assessing the Biosimilar Void. [Internet] IQVIA. 2023. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/assessing-the-biosimilar-void
3. Biosimilars Medicines Overview. A Biosimilar Medicine Is A Biological Medicine; It Is An Interchangeable Version Of An Already Approved Originator Biologic Medicine (Reference Medicine); The Reference Medicine And Biosimilar Medicine(S) Can Be Used Interchangeably Without A Patient Experiencing Any Changes In The Clinical Effect. [Internet] EMA. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview#:~:text=A percent20biosimilar percent20is percent20a percent20biological,apply percent20to percent20all percent20biological percent20medicines.
4. 2024 IQVIA Report: The Impact of Biosimilar Competition in Europe. [Internet] IQVIA. 2025. Available from: https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2024
5. (DG SANTE) Biosimilar Medicines – Multistakeholder Event (2024). [Internet] European Commission. 2024. Available from: https://health.ec.europa.eu/events/biosimilar-medicines-multistakeholder-event-2024-12-05_en
6. (DG GROW) Multi-Stakeholder Workshop – Access to and Uptake of Biosimilar Medicinal Products. [Internet] European Commission. 2015. Available from: https://ec.europa.eu/newsroom/growth/items/460858/en
7. Better Access to Medicines for Patients in Europe. [Internet] European Commission. 2013. Available from: https://ec.europa.eu/docsroom/documents/3982/attachments/1/translations/en/renditions/native
8. Capacity Building to Support the Uptake of Biosimilars in a Multistakeholder Approach. [Internet] AUGMENT Consortium. Available from: https://biosimilars.goeg.at/
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.